BB Biotech AGXSWX:BION +2.14%33 Net Margin % is 125.46% as of Mar. 2026, which is 26% above its 10-year median of 99.96. GuruFocus rates XSWX:BION with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, BB Biotech AG ranks better than 97.36% on this metric.
Net margin is calculated as Net Income divided by its Revenue. BB Biotech AG's Net Income for the
three
months ended in Mar. 2026 was CHF-21.4 Mil. BB Biotech AG's Revenue for the
three
months ended in Mar. 2026 was CHF-17.0 Mil. Therefore, BB Biotech AG's net margin for the quarter that ended in Mar. 2026 was 125.46%.
The historical rank and industry rank for BB Biotech AG's Net Margin % or its related term are showing as below:
XSWX:BION'
s Net Margin % Range Over the Past 10 Years
Min: 92.2 Med: 99.96 Max: 103.53
Current: 97.47
XSWX:BION's Net Margin % is ranked better than 97.36% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs XSWX:BION: 97.47
BB Biotech AG (XSWX:BION) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
BB Biotech AG Net Margin % Related Terms
BB Biotech AG Net Margin % Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BION vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, BB Biotech AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (XSWX:BION) has a Net Margin % of 125.46% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on BB Biotech AG and its competitors. This is 26% above median its historical median of 99.96. Over the past decade, BB Biotech AG's Net Margin % has ranged from 92.20 to 103.53. According to the industry distribution chart, BB Biotech AG ranks #25 out of 946 companies in the Biotechnology industry, placing it in the top 2.6%.
Is BB Biotech AG's Net Margin % too high?
BB Biotech AG's current Net Margin % of 125.46% is 26% above median its 10-year median of 99.96. Over the past 10 years, this metric has ranged from a low of 92.20 to a high of 103.53. Based on the distribution chart, BB Biotech AG ranks #25 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BB Biotech AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #25 out of 946 companies for Net Margin %. This places BB Biotech AG in the top 3% of its industry — outperforming the majority of peers. Historically, BB Biotech AG's own Net Margin % has ranged from 92.20 to 103.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on BB Biotech AG and its competitors. BB Biotech AG's current Net Margin % is 125.46%, which is 26% above median its own 10-year median of 99.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Net Margin % of 125.46%. The current Net Margin % is 125.46%, which is 26% above median its 10-year median of 99.96. BB Biotech AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Net Margin % is 125.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
33GF Score
Get the complete analysis for XSWX:BION
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 
